Carboplatin and Liposomal Doxorubicin for Ovarian Cancer. - Wikidata - awgldk - TriplyDB

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

http://www.wikidata.org/entity/Q37016053

about

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

http://www.wikidata.org/entity/Q37016053

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

@en

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

@nl

type

label

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

@en

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

@nl

prefLabel

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

@en

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

@nl

P1433

Q37016053-D273452B-A312-4775-B2CD-9E114A95A165

P1476

Q37016053-BDFF2F59-71FC-4709-B856-B6A7581A5F46

P2093

Q37016053-AE8FC59F-FFA6-4CCE-8E16-450DF9B3677B

Q37016053-BE8A04DA-4CD9-4CBC-B0FE-243FC2382503

Q37016053-DAE6541E-1940-470A-AED0-E9B8CAF21A06

P2860

Q37016053-0E8310D7-26B8-46C2-AD31-BC28DDD7E261

Q37016053-18DAE7EF-7C2B-41E5-A238-52F99C45AE2D

Q37016053-2C5EE77F-739E-4266-8AB6-678BFA65935D

Q37016053-2CC4EE4E-B815-4067-9B03-543C38C986F5

Q37016053-37B65E28-6038-4531-BBB7-A97AABD90956

Q37016053-3EF29714-8495-4080-A516-B9C052C6896A

Q37016053-55ABAB8C-3D21-46FE-9B4E-5D2DEEC74232

Q37016053-5841AEC8-41C9-4BB7-8560-40422B2FA08F

Q37016053-59F235A5-CCAB-42E1-81E2-221591B20944

Q37016053-74E5A264-86A5-4F8F-A6FB-323086BE4CA7

P304

Q37016053-2558F9F7-61DD-468C-8113-2B9F3B37BDDE

P31

Q37016053-10E89634-FE18-4F07-ADEB-6AA7CA38B653

P356

Q37016053-FF3D7571-1E77-41A4-B10D-8C990AD48F1A

P433

Q37016053-B5E84909-C18B-4552-A53C-B748E7E3250F

P478

Q37016053-21B42E26-D74C-4155-8EC2-227B6A5F8C30

P577

Q37016053-DDB5122F-64B3-4215-9CF0-B549BEF679A4

P698

Q37016053-DB3F06C9-C2E7-4CB3-A6B5-BA56279D9ECA

P921

Q37016053-AFA8EE6F-A792-490D-AE3D-8EAEABB238DF

P932

Q37016053-EE7D3DAF-BD85-402F-9EF4-EEAA29C6796F

P356

P1433

Hospital pharmacy

P1476

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

@en

P2093

Dominic A Solimando

http://www.w3.org/2001/XMLSchema#string

J Aubrey Waddell

http://www.w3.org/2001/XMLSchema#string

Jamie Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

Prediction of creatinine clearance from serum creatinine

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A

Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.

Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

P304

442-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HPJ5106-442

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27354744

http://www.w3.org/2001/XMLSchema#string

P921

P932

4911983

http://www.w3.org/2001/XMLSchema#string